EMAP-II is activated during apoptosis by cleavage of pro-EMAP through caspase 8 and enhances the recruitment of inflammatory cells by its chemotactic properties. Besides its chemotactic effect on inflammatory cells, EMAP-II increases the adhesiveness of coronary artery smooth muscle cells (CASMC) for monocytes. EMAP-II also has anti-angiogenic properties, which are explained by its pro-apoptotic effect on endothelial cells.
Alternative Names
Small inducible cytokine subfamily E member 1 ; SCYE1 ; EMAP II ; EMAP-2 ; Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 ; Multisynthase complex auxiliary component p43
Quantity
1.0 mg
Regulatory
RUO
Source
E. coli
Host
Human
Endotoxin Level
<1.0 EU/μg of recombinant protein as determined by the LAL method.
Biological Activity Comment
The ED(50) was determined by apoptotic effect on MCF-7 cells using a concentration of 10-50 ng/mL.
Weight
18.0 kDa
Description
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Format
Lyophilized PowderRecombinant EMAP-II was lyophilized from a 0.2 μm filtered 20 mM PB,130 mM NaCl solution pH 7.5.
Purity
>95% as determined by SDS-PAGE
Storage
The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.